ovarian%20cancer
OVARIAN CANCER
Ovarian cancer is a type of cancer that begins in the ovaries.
It is the 7th most common cancer in women (excluding skin cancer) and the leading cause of death from gynecologic cancer in developed countries.
The 3 histologic types of ovarian cancer are epithelial (primarily seen in women >50 years of age), germ cell (most commonly seen in women <20 years of age) and sex cord stromal (rare and produces steroid hormones).
The median age at the time of diagnosis is 63 years old and >70% present with advanced disease.

    Ovarian%20cancer Management

    Follow Up

    Epithelial Ovarian Carcinoma

    • Clinical evaluation every 2-4 months x 2 years, then every 3-6 months x 3 years; annually after 5 years
    • Monitoring includes:
      • PE with pelvic exam
      • Genetic risk evaluation if not done yet
      • If elevated initially, CA-125 every visit
      • As indicated: CBC, chemistry profile, CT scan, MRI, PET-CT, PET, chest x-ray
    • Long-term wellness care
    Germ Cell Ovarian Carcinoma
    • Dysgerminoma
      • 1st year: Every 2-3 months with PE, tumor markers1; radiographic imaging2; every 3-4 months with abdominal/pelvic CT
      • 2nd year: Every 3-4 months with PE, tumor markers1; radiographic imaging2; every 6 months with abdominal/pelvic CT
      • 3rd, 4th and 5 years: Every 6 months with PE, tumor markers1; radiographic imaging2; every year with abdominal/pelvic CT
      • Beyond 5 years: Every year with PE, tumor markers1; radiographic imaging2; abdominal/pelvic CT when clinically indicated
    • Non-dysgerminoma
      • 1st year: Every 2 months with PE, tumor markers1; radiographic imaging2; every 3-4 months with chest x-ray and abdominal/pelvic CT
      • 2nd year: Every 2 months with PE, tumor markers1; radiographic imaging2; every 4-6 months with chest x-ray and abdominal/pelvic CT
      • 3rd, 4th and 5 years: Every 4-6 months with PE, tumor markers1; radiographic imaging2; every 6-12 months with abdominal/pelvic CT
      • Beyond 5 years: Every year with PE, tumor markers1; radiographic imaging2; abdominal/pelvic CT when clinically indicated
    Sex Cord-Stromal Ovarian Carcinoma
    • PE when clinically indicated based on stage
      • Early stage/low risk - 6-12 months
      • High risk - 4-6 months
    • Tumor markers1 when clinically indicated or if applicable
    • Radiographic imaging2 only in patients with symptoms, elevated biomarkers or suspicious findings in PE
    1CA-125, beta-human chorionic gonadotropin (β-hCG), alpha-fetoprotein (AFP), inhibin, lactate dehydrogenase (LDH), carcinoembryonicantigen (CEA), CA 19-9
    2Chest X-ray, CT scan, MRI, PET-CT, or PET with contrast unless contraindicated
    Digital Edition
    Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
    Sign In To Download
    Editor's Recommendations
    Most Read Articles
    01 Dec 2020
    Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
    Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
    Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
    Jairia Dela Cruz, 3 days ago
    Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
    3 days ago
    Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.